Reviewing the role of healthy volunteer studies in drug development

Table 1 Selected trials of non-oncology drugs in healthy volunteers.

NCT number	Treatment	Target/MOA	Study design	Outcomes	Enrolled (N)
Completed clinical trials
NCT01396161	PF-05175157	Acetyl-CoA carboxylase inhibitor	Randomized, double-blind, placebo-controlled	PK, safety	64
NCT00741026	Olanzapine	Muscarinic (M3) receptor antagonist	Randomized, double-blind, placebo-controlled	PK, safety	15
NCT00894322	Exenatide	GLP-1 receptor agonist	Randomized, single-blind	PK, safety	65
NCT01380730	Evolocumab	PCSK9 monoclonal antibody inhibition	Randomized, quadruple-blind, placebo-controlled	PK, safety	629
NCT00924053	Bexagliflozin	SGLT-2 inhibitor	Randomized, quadruple-blind, placebo-controlled	PK, safety	24

GLP-1, glucagon-like peptide 1; MOA, mechanism of action; PCSK9, proprotein convertase subtilisin/kexin type 9; PK, pharmacokinetics; SGLT-2, sodium–glucose cotransporter-2

ISSN: 1479-5876